Table 3.
Effect of standardized plasma DOAC levels on the primary thrombotic outcome end point, adjusted for potential confounders
| Characteristic | First model (C-trough), n = 1657 |
Second model (C-peak), n = 1298 |
||
|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |
| Standardized C-trough DOAC | 0.56 | 0.37-0.86 | - | - |
| Standardized C-peak DOAC | - | - | 0.19 | 0.06-0.66 |
| CHA2DS2VASc score | 2.01 | 1.02-3.97 | 2.07 | 1.26-3.39 |
| BMI, kg/m2 | 0.93 | 0.80-1.08 | 0.95 | 0.82-1.09 |
| Glomerular filtration rate, mL/min | 1.02 | 1.00-1.05 | 1.02 | 0.99-1.05 |
| Low-dose vs standard dose DOAC | 3.49 | 0.76-16.0 | 2.72 | 0.55-13.5 |
| Antiplatelet treatment (yes vs no) | 0.28 | 0.03-2.53 | 0.25 | 0.03-1.81 |
Both models were estimated using the Fine and Gray competitive risk regression model. The Akaike information criteria was 118.4 and 106.1 for the models using C-trough and C-peak, respectively.
The inclusion of enrollment center as a potential confounder was not significant (P > 0.9 for both models) and it is not reported because it did not materially change estimates.
CI, confidence interval; HR, hazard ratio.